• AtriCure's November 4 third-quarter 2026 earnings call featured CEO Michael Carrel, CFO Angie Wirick and equity analysts.
• Quarterly revenue rose 15% to $154.5 million, driven by pain management, open ablation and appendage management.
• Management raised full-year adjusted EBITDA guidance to $91 million-$94 million; revenue is now expected at $606 million-$610 million.
• The outlook remains cautious amid U.S. hybrid ablation weakness and international headwinds, with no significant overseas recovery expected this year.
• BoxX-NoAF enrollment remains on track for year-end completion, with initial data expected in spring 2027; FDA approval is anticipated around mid-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AtriCure Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.